{"ticker": {"uuid": "461e5e74-fd70-4b83-a0ef-4528360582bc", "symbol": "FATE", "name": "Fate Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility \u2014 ORCL, SBUX, WULF, PANW, FATE In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPcTFjVTFfZllGajVyeXVtTndGY3JIR0tHWUxWZ01qLXFoekdod2RRTGl4RjVfUkc3YlFrUXVoN1k3c1A5NnlZVnd1REZBVm51bTJXZlJEblNkVXRDanNNT01RVlV0cm8xUVlkWThxTkU2akdCNlBkODNlbVZoTnozeldUTUZJbktKWUQyX3JtU0UtSllQa2FxRzR3MjRvQm1iM1pOU08ta1VpV3RHdi1DRG9MZ3JPeXZrTHY0UDBSZzE3Wmxfc2c3UDNsbXpaMDhkMnMxS1lfUWNVMXkwdFpoQlN5RGNPSllaRXFtRW9aQnFubnlC?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-15T09:14:40+00:00", "published_display": "15 Jul 2026 09:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BlackRock, Inc. Reduces Stake in Fate Therapeutics Inc", "summary": "BlackRock, Inc. has significantly reduced its stake in Fate Therapeutics Inc by selling 7,874,330 shares at $2.70 per share, leaving them with 2,194,284 shares. This move suggests a strategic reevaluation of its investment in the biopharmaceutical company, which is currently cons", "url": "https://www.gurufocus.com/news/8958985/blackrock-inc-reduces-stake-in-fate-therapeutics-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T00:45:28", "published_display": "15 Jul 2026 00:45", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves clinical testing of CAR T-cell therapy for AAV, other conditions", "summary": "The FDA has approved the initiation of clinical testing for Fate Therapeutics\u2019 experimental off-the-shelf CAR T-cell therapy, FT839, for ANCA-associated vasculitis (AAV) and other autoimmune disorders. The company plans a basket Phase 1/2 trial to evaluate FT839, which is designe", "url": "https://ancavasculitisnews.com/news/fda-clears-clinical-testing-cell-therapy-aav-conditions/", "source_name": "ANCA Vasculitis News", "published_at": "2026-07-13T22:40:49", "published_display": "13 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $3.11", "summary": "Needham has reaffirmed its Hold rating on Fate Therapeutics (FATE.US) and set a target price of $3.11. This indicates that while the firm sees no immediate reason to sell, it also does not anticipate significant upward movement in the stock price in the near term.", "url": "https://www.moomoo.com/news/post/72780882/needham-maintains-fate-therapeutics-fateus-with-hold-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-10T14:10:31", "published_display": "10 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Fate Therapeutics stock rating at buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQWDNZYVU4bERZRkhTMGItOXRxNS1jN3hrUFhrallUclE2ZEpDUDNSSVdXcEFpS2dJblg4dUh5azYzVHdVUlF5N2xULWg4WExKcDJhX09HdDUwcUJOX3Bta3pRY2FwN3BQS2hmcXdiMEZvYUlRRWxDQ085OGlETENFYmtZa3pucTVyUEJqZzRSMXpzb25JVXFFUzF6VlVDanB3V3RJLWdjbnQ4OG5VZF83ektYNDFrUzVYREFZdXYzcw?oc=5", "source_name": "Investing.com", "published_at": "2026-07-10T12:17:02+00:00", "published_display": "10 Jul 2026 12:17", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics (FATE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $FATE", "summary": "This article provides an overview of Fate Therapeutics' (FATE) FDA-related milestones and regulatory updates for its drug candidates FT839, FT819, and FT522 in 2025 and 2026. It details recent FDA clearances, preclinical and clinical data presentations, and special designations l", "url": "https://www.marketbeat.com/stocks/NASDAQ/FATE/fda-events/", "source_name": "MarketBeat", "published_at": "2026-07-10T03:40:14", "published_display": "10 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate", "summary": "Fate Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for FT839, an off-the-shelf CAR T-cell product candidate designed to co-target CD19 and CD38 for autoimmune diseases and hematological malignancies. The company plans to initiate a", "url": "https://www.globenewswire.com/news-release/2026/07/09/3324792/0/en/fate-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-for-ft839-product-candidate.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T03:10:31", "published_display": "10 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839", "summary": "Fate Therapeutics (FATE) shares increased after the FDA cleared its Investigational New Drug (IND) application for FT839, an engineered B-cell lymphoma 2 (BCL2) inhibitor for solid tumors and lymphomas. This clearance allows Fate to begin a Phase 1 study, initiating a milestone p", "url": "https://www.moomoo.com/news/post/72732039/update-fate-therapeutics-shares-rise-after-fda-clears-investigational-new", "source_name": "Moomoo", "published_at": "2026-07-09T22:07:22", "published_display": "09 Jul 2026 22:07", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839", "summary": "Fate Therapeutics (NASDAQ:FATE) shares increased after the FDA cleared its Investigational New Drug (IND) application for FT839, an iPSC-derived CAR T-cell product candidate targeting MICA and MICB proteins for solid tumors. The company is a clinical-stage biopharmaceutical firm ", "url": "https://www.marketscreener.com/news/fate-therapeutics-shares-rise-after-fda-clears-investigational-new-drug-application-for-ft839-ce7f5ededa81f02c", "source_name": "marketscreener.com", "published_at": "2026-07-09T19:07:22", "published_display": "09 Jul 2026 19:07", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials", "summary": "Fate Therapeutics Inc (FATE) saw its stock jump 6% after the FDA approved its application to begin clinical trials for its cell therapy, FT839. This clearance allows the company to start an early-stage basket trial for multiple autoimmune diseases later in 2026. FT839 is designed", "url": "https://stocktwits.com/news-articles/markets/equity/fate-stock-jumps-as-fda-greenlights-moving-cell-therapy-to-clinical-trials/cZmYJDgR7ny", "source_name": "Stocktwits", "published_at": "2026-07-09T16:52:00", "published_display": "09 Jul 2026 16:52", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics gains after IND clearance (FATE:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPNXBQb3Y0UmdaY3F0Y2VkQUNwcmNTLVY3dWhmZXdhZkZmTUMzMU55NmZzNHR6c2Zqc0M5Z0V0UGk0QzM5MlhFOXlqQk9ZZ0I2amljRk1yNk1wSDE3d2lXdlRIVGtUMnprY1RRcDRzZ0pvOWVxT2hQLUI2OVdlSUNtag?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-09T14:38:06+00:00", "published_display": "09 Jul 2026 14:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears Fate Therapeutics' FT839 for autoimmune trial push", "summary": "Fate Therapeutics (NASDAQ: FATE) has received FDA clearance for its Investigational New Drug (IND) application for FT839, an off-the-shelf, dual-CAR T-cell product designed to target both CD19 and CD38. This clearance paves the way for a Phase 1/2 basket clinical trial, expected ", "url": "https://www.stocktitan.net/news/FATE/fate-therapeutics-receives-fda-clearance-of-investigational-new-drug-8ptqctrsbkuq.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:11:10", "published_display": "09 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade)", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPWmtGcjhHREsxeVg4dGtiN2FSQjdRRGxRQkVFNXpEejYxalZVVEpFZ1F6VmM2ZDkteFh4MlZXNG53dV90YmhORWQ1Y29qLTJzdzV2RjlrbW9wNTQ4dU1NTjNSMkJ1MjI1V3QxbDFuckhVM2xDanlfVmpraExmU2xHLWM3VmJrbURXYXBKa003aXliMVduX0JPOGZnM0J2MFVTWGUySEpVTlBtNFBPZlhBTFc4VDF2R3BsRW1nVEJuMk9IR3k2N0tQZVRlenU0RzA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-08T15:54:44+00:00", "published_display": "08 Jul 2026 15:54", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics looks to its pipeline as investors weigh long-term prospects", "summary": "Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell-based immunotherapies for oncology and hematology. Its stock performance is largely influenced by clinical trial news and regulatory progress, rather than broad market trends, due to i", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fate-therapeutics-looks-to-its-pipeline-as-investors-weigh-long-term/69717493", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T22:12:00", "published_display": "07 Jul 2026 22:12", "sentiment": "positive", "sentiment_pct": 61, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54", "summary": "Insiders at Fate Therapeutics (NASDAQ:FATE) have recently sold stock, with the President selling shares at a price below the current market value. Despite a recent 21% rise in the stock price, insider selling over the past year and relatively low insider ownership levels suggest ", "url": "https://www.sahmcapital.com/news/content/fate-therapeutics-insiders-benefit-from-selling-stock-at-us154-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-06T15:09:15", "published_display": "06 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting", "summary": "Fate Therapeutics announced preliminary clinical data from its FT819 off-the-shelf CAR T-cell product candidate for Systemic Sclerosis (SSc) will be presented at the ISSCR 2026 Annual Meeting. The data from the first four SSc patients showed encouraging clinical activity and a we", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322405/0/en/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-the-shelf-car-t-cell-product-candidate-for-systemic-sclerosis-at-the-isscr-2026-annual-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T12:11:07", "published_display": "06 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics to show early FT819 data in systemic sclerosis", "summary": "Fate Therapeutics (NASDAQ:FATE) will present preliminary Phase 1 clinical data for its off-the-shelf CAR T-cell candidate FT819 in systemic sclerosis (SSc) at the ISSCR 2026 Annual Meeting. Early data from four treatment-refractory patients showed all achieved rCRISS \u226525 and mean", "url": "https://www.stocktitan.net/news/FATE/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-mtahhl5tm0na.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:11:07", "published_display": "06 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics to Present Preliminary Clinical Data of", "summary": "Fate Therapeutics, Inc. announced that preliminary clinical data for its off-the-shelf CAR T-cell product candidate, FT819, will be presented at the ISSCR 2026 Annual Meeting. The data, focusing on the Systemic Sclerosis arm of its Phase 1 trial, shows favorable tolerability and ", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322405/24675/en/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-the-shelf-car-t-cell-product-candidate-for-systemic-sclerosis-at-the-isscr-2026-annual-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T12:10:49", "published_display": "06 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics focuses on cell-based immunotherapy and long-term growth prospects", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNdFhlTXBNdlZHTnNvT1JteFJQSXNDcmJqam5kakF6UWhZT0J5dk9WVWhPbS1hZWhOdTdqc3Bsc1ZCYTRfX3NySnNXTXFzWG5oSm1GbHB5aUNqbjRWLVlvLTNhYUlVNy1oakJvdHlJeUw1MU9Kd010Mks4TDhLb0JVSmV3a25DMVBBNXg5UG0yemxXNGFwVWNUU0VqSTdWakFBRGRWOHFYZXhadkl5WUdMRk10UTVDbTRkM3lFTGFuQTh3VXpTRENGX2pCM0sxZw?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-03T17:38:51+00:00", "published_display": "03 Jul 2026 17:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics lines up four investor conferences in Q3", "summary": "Fate Therapeutics (NASDAQ:FATE) announced its management will participate in four investor conferences during the third quarter of 2026, including events hosted by Leerink Partners, Wells Fargo, Cantor Fitzgerald, and H.C. Wainwright. These participations aim to increase the comp", "url": "https://www.stocktitan.net/news/FATE/fate-therapeutics-to-participate-in-upcoming-third-quarter-2026-oxkyk4z33v1y.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:11:00", "published_display": "01 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences", "summary": "Fate Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several investor conferences in the third quarter of 2026. Management will attend the Leerink Partners Therapeutics Forum, Wells Fargo 21st Annual Healthcare Conference, 12th Annual Cant", "url": "https://www.manilatimes.net/2026/07/02/tmt-newswire/globenewswire/fate-therapeutics-to-participate-in-upcoming-third-quarter-2026-conferences/2377119", "source_name": "The Manila Times", "published_at": "2026-07-01T20:11:00", "published_display": "01 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FATE Stock Price and Chart \u2014 NASDAQ:FATE", "summary": "This article provides an overview of Fate Therapeutics, Inc. (FATE) stock, including its current price, key financial statistics, and performance. It details the company's business in developing cellular immunotherapies for cancer and immune disorders, lists its founding members ", "url": "https://www.tradingview.com/symbols/NASDAQ-FATE/", "source_name": "TradingView", "published_at": "2026-07-01T12:40:53", "published_display": "01 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index", "summary": "Fate Therapeutics, Inc. (NasdaqGM:FATE) has been removed from the Russell 3000E Index. This announcement follows similar removals from the Russell 2000 Index and Russell 2000 Value Benchmark on the same day. The company, a clinical-stage biopharmaceutical firm, specializes in iPS", "url": "https://www.marketscreener.com/news/fate-therapeutics-inc-nasdaqgm-fate-dropped-from-russell-3000e-index-ce7f5fdfda88f626", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:12:35", "published_display": "29 Jun 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders", "summary": "Fate Therapeutics Inc. (FATE) stock increased by 11.76% after releasing positive early Phase 1 data for its FT836 cancer treatment in KRAS wild-type metastatic colorectal cancer, showing meaningful tumor reductions without conditioning chemotherapy. The company's strategic profil", "url": "https://stockstotrade.com/news/fatetherapeuticsinc-fate-news-2026_06_28/", "source_name": "StocksToTrade", "published_at": "2026-06-28T12:09:15", "published_display": "28 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index", "summary": "Fate Therapeutics, Inc. (NasdaqGM:FATE) has been removed from the Russell 2000 Dynamic Index. This news was published on June 28, 2026, at 08:53 pm EDT by S&P Capital IQ. The company is a clinical-stage biopharmaceutical firm focused on developing off-the-shelf, multiplexed-engin", "url": "https://www.marketscreener.com/news/fate-therapeutics-inc-nasdaqgm-fate-dropped-from-russell-2000-dynamic-index-ce7f5fded881f325", "source_name": "marketscreener.com", "published_at": "2026-06-28T08:53:00", "published_display": "28 Jun 2026 08:53", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History", "summary": "This page provides a comprehensive overview of Fate Therapeutics Inc (FATE) stock, including its current price, historical data, news, and key financial metrics. It details the company's financial performance, analyst ratings, valuation, and market statistics. FATE is a clinical-", "url": "https://www.benzinga.com/quote/FATE", "source_name": "Benzinga", "published_at": "2026-06-26T23:12:35", "published_display": "26 Jun 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T)", "summary": "This article provides financial actuals and estimates for Fate Therapeutics, Inc. (F6T) traded on the Dusseldorf Stock Exchange. It covers income statement, balance sheet, cash flow, and valuation metrics, along with analyst forecasts for its stock price. The article also details", "url": "https://www.tradingview.com/symbols/DUS-F6T/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:13", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Fate Therapeutics Inc (FATE), noting its current valuation score is 7.14, ranking 255 out of 387 in the Biotechnology & Medical Research industry. It gives the stock's current P/E ratio as -1.72, which is significantly below its rece", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fate/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-26T10:40:13", "published_display": "26 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T)", "summary": "This article provides an overview of Fate Therapeutics, Inc. (F6T) listed on the Tradegate Exchange, including its financial actuals, analyst estimates, and frequently asked questions. It details various financial metrics such as earnings, revenue, net income, EBITDA, and future ", "url": "https://www.tradingview.com/symbols/TRADEGATE-F6T/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:13", "published_display": "26 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Reaffirms Their Buy Rating on Fate Therapeutics (FATE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOUWVoNHlpcnFCelNNdkQ3OE9YZ0ZvbndwU0JRWmF0d3h1VzhkZlEzY0pxTFY4dUh5dFBqSzNLS1Nvd2xpNG1aSXJxcFNfR212SjlJSUNwWUtxN0JuZk9kcElsMUFzQVk1blljaWhKMUd1aWpKNldrSjJvYWhQelhPb3hXbzFWOWZtMTZKUEh4N1h2ZEFycEx1T0czLUtUZmx1Vi1sUXUwcEl5cEZVTlkxcUd2SkViZHR2X2lMdEFuOW5iVWR2NWtTeGRLVElhX2FrbTJWaDBXdEpmMXVTeFgwQWVlZW9Qdw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics\u2019s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNUVluS3ZNcW9XVjRqblJXTHZYOXc0bVdNUTQxSUdCeUhmYzlQaGRmS0wtelRDSXVaaEN1aEJPX0xfWFo1aEwwZUFVWkd6el9FT2lJcGQ1NDBkX0dudjQtbGRCRnBSeUIybWVBY1pJWFF1YTN2Y1duZnBSZGV1QlowT2l6QXZycWgwdGU0MzZzQ1R5MnBjUVdGU0JSN2F1dThnTWc4d3BFYw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Appoints Laura Hamill to Board of Directors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQYXZiSm00bHQ5ZTg4cUdQUDR1QmpVODRXb29wNGNYUV9lb3BYVDRFRElzdzBTQjRJSUEyQmwxN3pvdi1QTU1rUjlDNDAtRVRBVzhsYUlvSkFOWXRlNzBBRkxmOFk3bjJKWnhSTlJOclBaMDRmdDB3UWtSaWVRcHM3QmV2Y05vNVFudGRWTGQwQVNQN0d3ZTF5dExEZFI2SDktNTl0c1pNbkhaeXBkRFNaRlRGWktsZjg1V2VlbHFYTjVvLXZmNER6Qm5FMDNxSFV3QWFr?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near lo", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPVEpReEtHSVpaZXh1VWhHUHhQZGVwb09LUU1DNzduUW9sWEZtREJTZUpnVDlaakpmR2xfRmRBVU5VdE1sWHJnYWhlYjNKWHVrU1BXeDV2OVAweDJyV1M4SVh0T1RrbS1LN0tpdG40WW5BYThIdWV5bVd5SmQycU5RU0x4OGdzSS1sN3VybzVGeHpzTGk3Ykk0STRKcGJtYmdnYUhMRUVmSXdsZElyVW82ZndZUlZqSEtWVHc?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Reiterates \u201cBuy\u201d Rating On Fate Therapeutics (FATE) With $7 PT", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQRHBhaTV0cHNjU2NtbUF4czk5aHpnTGlyc0JrSEVrNnlBV3JtQ0R1VVBZTVVwRXB2Tks5VkNsdVVxU29BZERKOXhKQWNTVmhkMVR1Z1hJb3g0SEdmSzZ4RzJEWGx1N19mTm16NjI3RVBNU2JVM2t4ZWVGeDE5SThWX3pOR0ItYUVuOVhvekk4dG1POHFKT0tNZXBn?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fate-therapeutics-showcases-data-ft819-123000655.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:30:00+00:00", "published_display": "04 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new Fate Therapeutics hires get 67,300 stock-unit grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQbGhkdUpVSEhaRnNtaUZNMldkSzBrenRJTGNrQV9RSWhjaE5VNjB2LUw3RklhR1JXejI0Z2lGcUNrUkNHYmZ4UUE3TmozaHBVRGl0d1BzaFVsU1lMVzRMU2FseGZ1SmVlMXpaQWlLTXJKNUE0by12cW90ZkpHLThCYnRkLTZVMEQwbXgtY295Y2F4RFZvbkhZUjFLVWRLWXNmTXF0QWxyb2hlWnVYc0U2OUxGRTM0VVRk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNNVhjZW5ZS25PWVdrWndTcUdtNGZ3V2xheEtrUWFMTFhKUVZGa1VlZXdFYWEyeVE5YVNGQkxVNkhZUWEwZVlBX3YxSUJrTzZNVkkyYmpKanBhUDM5SUFmV0JtOHQyNjAyMkxLbE5JUXpyZ0NBU1dDWi1fS0R0dW9zV29wOTN1RFlpZW00Mkg0dllhMnNKdEkybGNtLTRVX3Y5UWc?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPak9KNEg5N1Q0SjJaVktHZUVQN1htQkNtU0d1Q21TclNTT0VfU3BEUUVGNUlKUnBhZnB2MzhvSl9EQnFtMDRWWlQwcFVwS2dSTm9ZVThmbUE1eXdpazVKZHBGbEF0UkZndVp2eUs0UW1scUxFMXRHd2tfOEUzc3hyaUs5ZEVWTW5Sc01RcTVJd3g3TWtTQXAzUjQ2UTVhV1JLN29oUXA3NW5PcnFORmtxbHd2WUVTbjJ4ckgxZmNQZExlUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fate Therapeutics earnings beat by $0.02, revenue topped estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPMHpXbzVjWE1kT1drNVFsWlRpX1VtUkJES21XOHlnZ0gyOFdmRVNOaG9WZE52ZzJjZUxoaUh4MjQwS0ZpWW50ejFLdmhUdDhIbFo1ZXBwNHF5RmRGWTNualNRYUIySU00UW9FUTF2Y084YXZfQTF3bUpEYlBMNHhlY2ItZl9xUEZfeExmMHlJMUlhanlWYTdWRnZPaUt0X3QyaVB5MDVGZmhQNHBGR3pGRw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics presents CAR T-cell therapy data at ASGCT", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNbkljX3lKUEVIMm1WbmpqZl8zV2tmNW82YUxJNGpSWkhIbnZQMUhnNGdvbnE3SnZPU1doWWQ5UVo0TXI1VEwwall6NndfZnR3NV9kRGdRYmZtb1FSRkJnQkJjUGNvQ0dSbExDU0lqbzUxVVc4c2NRcE05QjJNLTJaS3ExTExWU0VPaktuWkZtYk9tLVIzVGtVQVRfUjNzM0xVTjMzRndVWFdsTVhnTWM1MXM1VUNmdw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fate Therapeutics plans appearances at 5 investor conferences by June", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWFd4SWxSbFZUVjg1YktDcXhwM3MtcjBRNzgtYjZReWVJNVpRenl0QjAxWHI5dGktTC1pUXpUeDBQeUY1cHhGZVNxekR1c0s4eHhFb3MzWXhmRWRveVNadVh4U1pQaUF0Y1kwOUJYOWN1eFBibV9kRWhlc092Qzg1WGYxRHZIUDV6clp1dGVqb0ZidV9GaGNUTm9aTllkaTZQNEdKZWQxSnpyckhhTkZfRXpOSU1kUzJoQk9Z?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-25T08:00:00+00:00", "published_display": "25 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPVnlqM2xSeVQ1d0ZkTEFJZ1BPZU5Zbmtkb1JKWkZpVzdkc2JwUTZRcGdpT2F3N1FPMXEzVG9ueDJhdG10UVFSdzNDTm5sU0w5VVk1M2tyZWRVZFRtb3JvbmNlc3B5Q0NwOTBLdS1UUjcxNGMycENiWEI3UU52NWZNVzM0UVJGLWd0MmRwS1JKcE9fNlFzYnpXVXU4VzU0LURvWG42cUJ3WEM0WXo0NGdXeUdJYnktSC01ZEwyR0tjQ0N6eGhMc0JYcnpXdFZXMWJHWm9zLWJMYlFxOUt3MVVj?oc=5", "source_name": "Stocktwits", "published_at": "2025-04-14T07:00:00+00:00", "published_display": "14 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility \u2014 ORCL, SBUX, WULF, PANW, FATE In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPcTFjVTFfZllGajVyeXVtTndGY3JIR0tHWUxWZ01qLXFoekdod2RRTGl4RjVfUkc3YlFrUXVoN1k3c1A5NnlZVnd1REZBVm51bTJXZlJEblNkVXRDanNNT01RVlV0cm8xUVlkWThxTkU2akdCNlBkODNlbVZoTnozeldUTUZJbktKWUQyX3JtU0UtSllQa2FxRzR3MjRvQm1iM1pOU08ta1VpV3RHdi1DRG9MZ3JPeXZrTHY0UDBSZzE3Wmxfc2c3UDNsbXpaMDhkMnMxS1lfUWNVMXkwdFpoQlN5RGNPSllaRXFtRW9aQnFubnlC?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-15T09:14:40+00:00", "published_display": "15 Jul 2026 09:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BlackRock, Inc. Reduces Stake in Fate Therapeutics Inc", "summary": "BlackRock, Inc. has significantly reduced its stake in Fate Therapeutics Inc by selling 7,874,330 shares at $2.70 per share, leaving them with 2,194,284 shares. This move suggests a strategic reevaluation of its investment in the biopharmaceutical company, which is currently cons", "url": "https://www.gurufocus.com/news/8958985/blackrock-inc-reduces-stake-in-fate-therapeutics-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T00:45:28", "published_display": "15 Jul 2026 00:45", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves clinical testing of CAR T-cell therapy for AAV, other conditions", "summary": "The FDA has approved the initiation of clinical testing for Fate Therapeutics\u2019 experimental off-the-shelf CAR T-cell therapy, FT839, for ANCA-associated vasculitis (AAV) and other autoimmune disorders. The company plans a basket Phase 1/2 trial to evaluate FT839, which is designe", "url": "https://ancavasculitisnews.com/news/fda-clears-clinical-testing-cell-therapy-aav-conditions/", "source_name": "ANCA Vasculitis News", "published_at": "2026-07-13T22:40:49", "published_display": "13 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $3.11", "summary": "Needham has reaffirmed its Hold rating on Fate Therapeutics (FATE.US) and set a target price of $3.11. This indicates that while the firm sees no immediate reason to sell, it also does not anticipate significant upward movement in the stock price in the near term.", "url": "https://www.moomoo.com/news/post/72780882/needham-maintains-fate-therapeutics-fateus-with-hold-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-10T14:10:31", "published_display": "10 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Fate Therapeutics stock rating at buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQWDNZYVU4bERZRkhTMGItOXRxNS1jN3hrUFhrallUclE2ZEpDUDNSSVdXcEFpS2dJblg4dUh5azYzVHdVUlF5N2xULWg4WExKcDJhX09HdDUwcUJOX3Bta3pRY2FwN3BQS2hmcXdiMEZvYUlRRWxDQ085OGlETENFYmtZa3pucTVyUEJqZzRSMXpzb25JVXFFUzF6VlVDanB3V3RJLWdjbnQ4OG5VZF83ektYNDFrUzVYREFZdXYzcw?oc=5", "source_name": "Investing.com", "published_at": "2026-07-10T12:17:02+00:00", "published_display": "10 Jul 2026 12:17", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics (FATE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $FATE", "summary": "This article provides an overview of Fate Therapeutics' (FATE) FDA-related milestones and regulatory updates for its drug candidates FT839, FT819, and FT522 in 2025 and 2026. It details recent FDA clearances, preclinical and clinical data presentations, and special designations l", "url": "https://www.marketbeat.com/stocks/NASDAQ/FATE/fda-events/", "source_name": "MarketBeat", "published_at": "2026-07-10T03:40:14", "published_display": "10 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate", "summary": "Fate Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for FT839, an off-the-shelf CAR T-cell product candidate designed to co-target CD19 and CD38 for autoimmune diseases and hematological malignancies. The company plans to initiate a", "url": "https://www.globenewswire.com/news-release/2026/07/09/3324792/0/en/fate-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-for-ft839-product-candidate.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T03:10:31", "published_display": "10 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839", "summary": "Fate Therapeutics (FATE) shares increased after the FDA cleared its Investigational New Drug (IND) application for FT839, an engineered B-cell lymphoma 2 (BCL2) inhibitor for solid tumors and lymphomas. This clearance allows Fate to begin a Phase 1 study, initiating a milestone p", "url": "https://www.moomoo.com/news/post/72732039/update-fate-therapeutics-shares-rise-after-fda-clears-investigational-new", "source_name": "Moomoo", "published_at": "2026-07-09T22:07:22", "published_display": "09 Jul 2026 22:07", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839", "summary": "Fate Therapeutics (NASDAQ:FATE) shares increased after the FDA cleared its Investigational New Drug (IND) application for FT839, an iPSC-derived CAR T-cell product candidate targeting MICA and MICB proteins for solid tumors. The company is a clinical-stage biopharmaceutical firm ", "url": "https://www.marketscreener.com/news/fate-therapeutics-shares-rise-after-fda-clears-investigational-new-drug-application-for-ft839-ce7f5ededa81f02c", "source_name": "marketscreener.com", "published_at": "2026-07-09T19:07:22", "published_display": "09 Jul 2026 19:07", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials", "summary": "Fate Therapeutics Inc (FATE) saw its stock jump 6% after the FDA approved its application to begin clinical trials for its cell therapy, FT839. This clearance allows the company to start an early-stage basket trial for multiple autoimmune diseases later in 2026. FT839 is designed", "url": "https://stocktwits.com/news-articles/markets/equity/fate-stock-jumps-as-fda-greenlights-moving-cell-therapy-to-clinical-trials/cZmYJDgR7ny", "source_name": "Stocktwits", "published_at": "2026-07-09T16:52:00", "published_display": "09 Jul 2026 16:52", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics gains after IND clearance (FATE:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPNXBQb3Y0UmdaY3F0Y2VkQUNwcmNTLVY3dWhmZXdhZkZmTUMzMU55NmZzNHR6c2Zqc0M5Z0V0UGk0QzM5MlhFOXlqQk9ZZ0I2amljRk1yNk1wSDE3d2lXdlRIVGtUMnprY1RRcDRzZ0pvOWVxT2hQLUI2OVdlSUNtag?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-09T14:38:06+00:00", "published_display": "09 Jul 2026 14:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears Fate Therapeutics' FT839 for autoimmune trial push", "summary": "Fate Therapeutics (NASDAQ: FATE) has received FDA clearance for its Investigational New Drug (IND) application for FT839, an off-the-shelf, dual-CAR T-cell product designed to target both CD19 and CD38. This clearance paves the way for a Phase 1/2 basket clinical trial, expected ", "url": "https://www.stocktitan.net/news/FATE/fate-therapeutics-receives-fda-clearance-of-investigational-new-drug-8ptqctrsbkuq.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:11:10", "published_display": "09 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade)", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPWmtGcjhHREsxeVg4dGtiN2FSQjdRRGxRQkVFNXpEejYxalZVVEpFZ1F6VmM2ZDkteFh4MlZXNG53dV90YmhORWQ1Y29qLTJzdzV2RjlrbW9wNTQ4dU1NTjNSMkJ1MjI1V3QxbDFuckhVM2xDanlfVmpraExmU2xHLWM3VmJrbURXYXBKa003aXliMVduX0JPOGZnM0J2MFVTWGUySEpVTlBtNFBPZlhBTFc4VDF2R3BsRW1nVEJuMk9IR3k2N0tQZVRlenU0RzA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-08T15:54:44+00:00", "published_display": "08 Jul 2026 15:54", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics looks to its pipeline as investors weigh long-term prospects", "summary": "Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell-based immunotherapies for oncology and hematology. Its stock performance is largely influenced by clinical trial news and regulatory progress, rather than broad market trends, due to i", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fate-therapeutics-looks-to-its-pipeline-as-investors-weigh-long-term/69717493", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T22:12:00", "published_display": "07 Jul 2026 22:12", "sentiment": "positive", "sentiment_pct": 61, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54", "summary": "Insiders at Fate Therapeutics (NASDAQ:FATE) have recently sold stock, with the President selling shares at a price below the current market value. Despite a recent 21% rise in the stock price, insider selling over the past year and relatively low insider ownership levels suggest ", "url": "https://www.sahmcapital.com/news/content/fate-therapeutics-insiders-benefit-from-selling-stock-at-us154-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-06T15:09:15", "published_display": "06 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting", "summary": "Fate Therapeutics announced preliminary clinical data from its FT819 off-the-shelf CAR T-cell product candidate for Systemic Sclerosis (SSc) will be presented at the ISSCR 2026 Annual Meeting. The data from the first four SSc patients showed encouraging clinical activity and a we", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322405/0/en/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-the-shelf-car-t-cell-product-candidate-for-systemic-sclerosis-at-the-isscr-2026-annual-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T12:11:07", "published_display": "06 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics to show early FT819 data in systemic sclerosis", "summary": "Fate Therapeutics (NASDAQ:FATE) will present preliminary Phase 1 clinical data for its off-the-shelf CAR T-cell candidate FT819 in systemic sclerosis (SSc) at the ISSCR 2026 Annual Meeting. Early data from four treatment-refractory patients showed all achieved rCRISS \u226525 and mean", "url": "https://www.stocktitan.net/news/FATE/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-mtahhl5tm0na.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:11:07", "published_display": "06 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics to Present Preliminary Clinical Data of", "summary": "Fate Therapeutics, Inc. announced that preliminary clinical data for its off-the-shelf CAR T-cell product candidate, FT819, will be presented at the ISSCR 2026 Annual Meeting. The data, focusing on the Systemic Sclerosis arm of its Phase 1 trial, shows favorable tolerability and ", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322405/24675/en/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-the-shelf-car-t-cell-product-candidate-for-systemic-sclerosis-at-the-isscr-2026-annual-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T12:10:49", "published_display": "06 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics focuses on cell-based immunotherapy and long-term growth prospects", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNdFhlTXBNdlZHTnNvT1JteFJQSXNDcmJqam5kakF6UWhZT0J5dk9WVWhPbS1hZWhOdTdqc3Bsc1ZCYTRfX3NySnNXTXFzWG5oSm1GbHB5aUNqbjRWLVlvLTNhYUlVNy1oakJvdHlJeUw1MU9Kd010Mks4TDhLb0JVSmV3a25DMVBBNXg5UG0yemxXNGFwVWNUU0VqSTdWakFBRGRWOHFYZXhadkl5WUdMRk10UTVDbTRkM3lFTGFuQTh3VXpTRENGX2pCM0sxZw?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-03T17:38:51+00:00", "published_display": "03 Jul 2026 17:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics lines up four investor conferences in Q3", "summary": "Fate Therapeutics (NASDAQ:FATE) announced its management will participate in four investor conferences during the third quarter of 2026, including events hosted by Leerink Partners, Wells Fargo, Cantor Fitzgerald, and H.C. Wainwright. These participations aim to increase the comp", "url": "https://www.stocktitan.net/news/FATE/fate-therapeutics-to-participate-in-upcoming-third-quarter-2026-oxkyk4z33v1y.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:11:00", "published_display": "01 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences", "summary": "Fate Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several investor conferences in the third quarter of 2026. Management will attend the Leerink Partners Therapeutics Forum, Wells Fargo 21st Annual Healthcare Conference, 12th Annual Cant", "url": "https://www.manilatimes.net/2026/07/02/tmt-newswire/globenewswire/fate-therapeutics-to-participate-in-upcoming-third-quarter-2026-conferences/2377119", "source_name": "The Manila Times", "published_at": "2026-07-01T20:11:00", "published_display": "01 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FATE Stock Price and Chart \u2014 NASDAQ:FATE", "summary": "This article provides an overview of Fate Therapeutics, Inc. (FATE) stock, including its current price, key financial statistics, and performance. It details the company's business in developing cellular immunotherapies for cancer and immune disorders, lists its founding members ", "url": "https://www.tradingview.com/symbols/NASDAQ-FATE/", "source_name": "TradingView", "published_at": "2026-07-01T12:40:53", "published_display": "01 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index", "summary": "Fate Therapeutics, Inc. (NasdaqGM:FATE) has been removed from the Russell 3000E Index. This announcement follows similar removals from the Russell 2000 Index and Russell 2000 Value Benchmark on the same day. The company, a clinical-stage biopharmaceutical firm, specializes in iPS", "url": "https://www.marketscreener.com/news/fate-therapeutics-inc-nasdaqgm-fate-dropped-from-russell-3000e-index-ce7f5fdfda88f626", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:12:35", "published_display": "29 Jun 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders", "summary": "Fate Therapeutics Inc. (FATE) stock increased by 11.76% after releasing positive early Phase 1 data for its FT836 cancer treatment in KRAS wild-type metastatic colorectal cancer, showing meaningful tumor reductions without conditioning chemotherapy. The company's strategic profil", "url": "https://stockstotrade.com/news/fatetherapeuticsinc-fate-news-2026_06_28/", "source_name": "StocksToTrade", "published_at": "2026-06-28T12:09:15", "published_display": "28 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index", "summary": "Fate Therapeutics, Inc. (NasdaqGM:FATE) has been removed from the Russell 2000 Dynamic Index. This news was published on June 28, 2026, at 08:53 pm EDT by S&P Capital IQ. The company is a clinical-stage biopharmaceutical firm focused on developing off-the-shelf, multiplexed-engin", "url": "https://www.marketscreener.com/news/fate-therapeutics-inc-nasdaqgm-fate-dropped-from-russell-2000-dynamic-index-ce7f5fded881f325", "source_name": "marketscreener.com", "published_at": "2026-06-28T08:53:00", "published_display": "28 Jun 2026 08:53", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History", "summary": "This page provides a comprehensive overview of Fate Therapeutics Inc (FATE) stock, including its current price, historical data, news, and key financial metrics. It details the company's financial performance, analyst ratings, valuation, and market statistics. FATE is a clinical-", "url": "https://www.benzinga.com/quote/FATE", "source_name": "Benzinga", "published_at": "2026-06-26T23:12:35", "published_display": "26 Jun 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T)", "summary": "This article provides financial actuals and estimates for Fate Therapeutics, Inc. (F6T) traded on the Dusseldorf Stock Exchange. It covers income statement, balance sheet, cash flow, and valuation metrics, along with analyst forecasts for its stock price. The article also details", "url": "https://www.tradingview.com/symbols/DUS-F6T/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:13", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Fate Therapeutics Inc (FATE), noting its current valuation score is 7.14, ranking 255 out of 387 in the Biotechnology & Medical Research industry. It gives the stock's current P/E ratio as -1.72, which is significantly below its rece", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fate/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-26T10:40:13", "published_display": "26 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T)", "summary": "This article provides an overview of Fate Therapeutics, Inc. (F6T) listed on the Tradegate Exchange, including its financial actuals, analyst estimates, and frequently asked questions. It details various financial metrics such as earnings, revenue, net income, EBITDA, and future ", "url": "https://www.tradingview.com/symbols/TRADEGATE-F6T/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:13", "published_display": "26 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Reaffirms Their Buy Rating on Fate Therapeutics (FATE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOUWVoNHlpcnFCelNNdkQ3OE9YZ0ZvbndwU0JRWmF0d3h1VzhkZlEzY0pxTFY4dUh5dFBqSzNLS1Nvd2xpNG1aSXJxcFNfR212SjlJSUNwWUtxN0JuZk9kcElsMUFzQVk1blljaWhKMUd1aWpKNldrSjJvYWhQelhPb3hXbzFWOWZtMTZKUEh4N1h2ZEFycEx1T0czLUtUZmx1Vi1sUXUwcEl5cEZVTlkxcUd2SkViZHR2X2lMdEFuOW5iVWR2NWtTeGRLVElhX2FrbTJWaDBXdEpmMXVTeFgwQWVlZW9Qdw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics\u2019s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNUVluS3ZNcW9XVjRqblJXTHZYOXc0bVdNUTQxSUdCeUhmYzlQaGRmS0wtelRDSXVaaEN1aEJPX0xfWFo1aEwwZUFVWkd6el9FT2lJcGQ1NDBkX0dudjQtbGRCRnBSeUIybWVBY1pJWFF1YTN2Y1duZnBSZGV1QlowT2l6QXZycWgwdGU0MzZzQ1R5MnBjUVdGU0JSN2F1dThnTWc4d3BFYw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Appoints Laura Hamill to Board of Directors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQYXZiSm00bHQ5ZTg4cUdQUDR1QmpVODRXb29wNGNYUV9lb3BYVDRFRElzdzBTQjRJSUEyQmwxN3pvdi1QTU1rUjlDNDAtRVRBVzhsYUlvSkFOWXRlNzBBRkxmOFk3bjJKWnhSTlJOclBaMDRmdDB3UWtSaWVRcHM3QmV2Y05vNVFudGRWTGQwQVNQN0d3ZTF5dExEZFI2SDktNTl0c1pNbkhaeXBkRFNaRlRGWktsZjg1V2VlbHFYTjVvLXZmNER6Qm5FMDNxSFV3QWFr?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near lo", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPVEpReEtHSVpaZXh1VWhHUHhQZGVwb09LUU1DNzduUW9sWEZtREJTZUpnVDlaakpmR2xfRmRBVU5VdE1sWHJnYWhlYjNKWHVrU1BXeDV2OVAweDJyV1M4SVh0T1RrbS1LN0tpdG40WW5BYThIdWV5bVd5SmQycU5RU0x4OGdzSS1sN3VybzVGeHpzTGk3Ykk0STRKcGJtYmdnYUhMRUVmSXdsZElyVW82ZndZUlZqSEtWVHc?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Reiterates \u201cBuy\u201d Rating On Fate Therapeutics (FATE) With $7 PT", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQRHBhaTV0cHNjU2NtbUF4czk5aHpnTGlyc0JrSEVrNnlBV3JtQ0R1VVBZTVVwRXB2Tks5VkNsdVVxU29BZERKOXhKQWNTVmhkMVR1Z1hJb3g0SEdmSzZ4RzJEWGx1N19mTm16NjI3RVBNU2JVM2t4ZWVGeDE5SThWX3pOR0ItYUVuOVhvekk4dG1POHFKT0tNZXBn?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fate-therapeutics-showcases-data-ft819-123000655.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:30:00+00:00", "published_display": "04 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new Fate Therapeutics hires get 67,300 stock-unit grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQbGhkdUpVSEhaRnNtaUZNMldkSzBrenRJTGNrQV9RSWhjaE5VNjB2LUw3RklhR1JXejI0Z2lGcUNrUkNHYmZ4UUE3TmozaHBVRGl0d1BzaFVsU1lMVzRMU2FseGZ1SmVlMXpaQWlLTXJKNUE0by12cW90ZkpHLThCYnRkLTZVMEQwbXgtY295Y2F4RFZvbkhZUjFLVWRLWXNmTXF0QWxyb2hlWnVYc0U2OUxGRTM0VVRk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNNVhjZW5ZS25PWVdrWndTcUdtNGZ3V2xheEtrUWFMTFhKUVZGa1VlZXdFYWEyeVE5YVNGQkxVNkhZUWEwZVlBX3YxSUJrTzZNVkkyYmpKanBhUDM5SUFmV0JtOHQyNjAyMkxLbE5JUXpyZ0NBU1dDWi1fS0R0dW9zV29wOTN1RFlpZW00Mkg0dllhMnNKdEkybGNtLTRVX3Y5UWc?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPak9KNEg5N1Q0SjJaVktHZUVQN1htQkNtU0d1Q21TclNTT0VfU3BEUUVGNUlKUnBhZnB2MzhvSl9EQnFtMDRWWlQwcFVwS2dSTm9ZVThmbUE1eXdpazVKZHBGbEF0UkZndVp2eUs0UW1scUxFMXRHd2tfOEUzc3hyaUs5ZEVWTW5Sc01RcTVJd3g3TWtTQXAzUjQ2UTVhV1JLN29oUXA3NW5PcnFORmtxbHd2WUVTbjJ4ckgxZmNQZExlUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics earnings beat by $0.02, revenue topped estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPMHpXbzVjWE1kT1drNVFsWlRpX1VtUkJES21XOHlnZ0gyOFdmRVNOaG9WZE52ZzJjZUxoaUh4MjQwS0ZpWW50ejFLdmhUdDhIbFo1ZXBwNHF5RmRGWTNualNRYUIySU00UW9FUTF2Y084YXZfQTF3bUpEYlBMNHhlY2ItZl9xUEZfeExmMHlJMUlhanlWYTdWRnZPaUt0X3QyaVB5MDVGZmhQNHBGR3pGRw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics presents CAR T-cell therapy data at ASGCT", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNbkljX3lKUEVIMm1WbmpqZl8zV2tmNW82YUxJNGpSWkhIbnZQMUhnNGdvbnE3SnZPU1doWWQ5UVo0TXI1VEwwall6NndfZnR3NV9kRGdRYmZtb1FSRkJnQkJjUGNvQ0dSbExDU0lqbzUxVVc4c2NRcE05QjJNLTJaS3ExTExWU0VPaktuWkZtYk9tLVIzVGtVQVRfUjNzM0xVTjMzRndVWFdsTVhnTWM1MXM1VUNmdw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics plans appearances at 5 investor conferences by June", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWFd4SWxSbFZUVjg1YktDcXhwM3MtcjBRNzgtYjZReWVJNVpRenl0QjAxWHI5dGktTC1pUXpUeDBQeUY1cHhGZVNxekR1c0s4eHhFb3MzWXhmRWRveVNadVh4U1pQaUF0Y1kwOUJYOWN1eFBibV9kRWhlc092Qzg1WGYxRHZIUDV6clp1dGVqb0ZidV9GaGNUTm9aTllkaTZQNEdKZWQxSnpyckhhTkZfRXpOSU1kUzJoQk9Z?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-25T08:00:00+00:00", "published_display": "25 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPVnlqM2xSeVQ1d0ZkTEFJZ1BPZU5Zbmtkb1JKWkZpVzdkc2JwUTZRcGdpT2F3N1FPMXEzVG9ueDJhdG10UVFSdzNDTm5sU0w5VVk1M2tyZWRVZFRtb3JvbmNlc3B5Q0NwOTBLdS1UUjcxNGMycENiWEI3UU52NWZNVzM0UVJGLWd0MmRwS1JKcE9fNlFzYnpXVXU4VzU0LURvWG42cUJ3WEM0WXo0NGdXeUdJYnktSC01ZEwyR0tjQ0N6eGhMc0JYcnpXdFZXMWJHWm9zLWJMYlFxOUt3MVVj?oc=5", "source_name": "Stocktwits", "published_at": "2025-04-14T07:00:00+00:00", "published_display": "14 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 53, "sentiment_summary": {"positive": 22, "negative": 6, "neutral": 25, "score": 58, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 14.45, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 4.2, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 3.1, "latest_week": "2026-07-10", "one_week_move": 6.2, "four_week_move": 50.5, "twelve_week_move": 123.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.139772, "market_dynamics_buy_signal": false, "relative_strength": 92.589931, "fair_value_gap": 23.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.1543, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.2% over one week, +50.5% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "GlobeNewswire", "count": 5}, {"label": "Stock Titan", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "Stocktwits", "count": 3}, {"label": "Seeking Alpha", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 6}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.2% over one week, +50.5% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility \u2014 ORCL, SBUX, WULF, PANW, FATE In Focus"}], "updated_at": "2026-07-16T14:31:04.500135+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}